Background. The purpose of this study was to present 12-month and lifetime estimates of the prevalence, sociodemographic and clinical correlates, and psychiatric co-morbidity of DSM-IV cannabis abuse and dependence. Method. Data were derived from a large nationally representative survey ( n =43093) of US adults. Results. The prevalence of 12-month and lifetime DSM-IV cannabis abuse (1·1% and 7·2%) exceeded the corresponding rates of cannabis dependence (0·3% and 1·3%). Being male, Native American, widowed/separated/divorced, and residing in the West increased the odds whereas being Black, Asian or Hispanic decreased the odds of cannabis abuse and dependence. Cannabis dependence was significantly associated with low income. Ages of onset for both cannabis use disorders occurred in adolescence and the majority of individuals with these disorders remained untreated. Co-morbidity was high between cannabis use disorders and other Axis I and II disorders. Conclusions. Cannabis use disorders continue to present a widespread and serious personal and public health problem. Native Americans were found to have high rates of cannabis use disorders, warranting closer attention to the mental health needs of this subgroup. Associations between cannabis abuse and dependence and Axis I and II disorders were strong, signaling the need for more comprehensive assessment of individuals with cannabis use disorders. Further controlled treatment studies are needed, especially among co-morbid individuals, in view of growing evidence of the adverse personal, medical and societal impacts of cannabis use disorders in the USA.

Cannabis use disorders in the USA: prevalence, correlates and co-morbidity.

Objective: This study estimates the prevalence of depression and describes the correlates and independent associations of distress and depression among U.S. men who have sex with men. Method: A household-based probability sample of men who have sex with men (N=2,881) was interviewed between 1996 and 1998 in four large American cities. With cutoff points of 15 and 22 for the Center for Epidemiological Studies Depression Scale, individual correlates and predictors of distress and depression were examined, and multinomial logistic regression was performed. Results: The 7-day prevalence of depression in men who have sex with men was 17.2%, higher than in adult U.S. men in general. Both distress and depression were associated with lack of a domestic partner; not identifying as gay, queer, or homosexual; experiencing multiple episodes of antigay violence in the previous 5 years; and very high levels of community alienation. Distress was also associated with being of other than Asian/Pacific Islander ethnicity and experiencing early antigay harassment. Depression was also associated with histories of attempted suicide, child abuse, and recent sexual dysfunction. Being HIV positive was correlated with distress and depression but not significantly when demographic characteristics, developmental history, substance use, sexual behavior, and current social context were controlled by logistic regression. Conclusions: Rates of distress and depression are high in men who have sex with men. These high rates have important public health ramifications. The predictors of distress and depression suggest prevention efforts that might be effective when aimed at men who have sex with men.

Distress and depression in men who have sex with men: the Urban Men's Health Study.

Myocardial infarction (MI) is a term used for an event of heart attack which is due to formation of plaques in the interior walls of the arteries resulting in reduced blood flow to the heart and injuring heart muscles because of lack of oxygen supply The symptoms of MI include chest pain, which travels from left arm to neck, shortness of breath, sweating, nausea, vomiting, abnormal heart beating, anxiety, fatigue, weakness, stress, depression, and other factors The immediate treatment of MI include, taking aspirin, which prevents blood from clotting, and nitro-glycerin to treat chest pain and oxygen The heart attack can be prevented by taking an earlier action to lower those risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, drugs, monitoring of blood pressure every week, doing exercise every day, and loosing body weight The treatment of MI includes, aspirin tablets, and to dissolve arterial blockage injection of thrombolytic or clot dissolving drugs such as tissue plasminogen activator, streptokinase or urokinase in blood within 3 h of the onset of a heart attack The painkillers such as morphine or meperidine can be administered to relieve pain Nitroglycerin and antihypertensive drugs such as beta-blockers, ACE inhibitors or calcium channel blockers may also be used to lower blood pressure and to improve the oxygen demand of heart The ECG, coronary angiography and X-ray of heart and blood vessels can be performed to observe the narrowing of coronary arteries In this article the causes, symptoms and treatments of MI are described

Myocardial Infarction: Symptoms and Treatments

Marijuana is the most widely used illicit drug, with approximately 200 million users worldwide. Once illegal throughout the United States, cannabis is now legal for medicinal purposes in several states and for recreational use in 3 states. The current wave of decriminalization may lead to more widespread use, and it is important that cardiologists be made aware of the potential for marijuana-associated adverse cardiovascular effects that may begin to occur in the population at a greater frequency. In this report, the investigators focus on the known cardiovascular, cerebrovascular, and peripheral effects of marijuana inhalation. Temporal associations between marijuana use and serious adverse events, including myocardial infarction, sudden cardiac death, cardiomyopathy, stroke, transient ischemic attack, and cannabis arteritis have been described. In conclusion, the potential for increased use of marijuana in the changing legal landscape suggests the need for the community to intensify research regarding the safety of marijuana use and for cardiologists to maintain an awareness of the potential for adverse effects.

Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know.

A variety of drugs targeted towards the central nervous system are associated with cardiac side effects, some of which are linked with reports of arrhythmia and sudden death. Some psychotropic drugs, particularly tricyclic antidepressants (TCAs) and antipsychotic agents, are correlated with iatrogenic prolongation of the QT interval of the electrocardiogram (ECG). In turn, this is associated with the arrhythmia (TdP). This review discusses the association between psychotropic agents, arrhythmia and sudden death and, focusing on TCAs and antipsychotics, considers their range of cellular actions on the heart; potentially pro-arrhythmic interactions between psychotropic and other medications are also considered. At the cellular level TCAs, such as imipramine and amitriptyline, and antipsychotics, such as thioridazine, are associated with inhibition of potassium channels encoded by In many cases this cellular action correlates with ECG changes and a risk of TdP. However, not all psychotropic agents that inhibit HERG at the cellular level are associated equally with QT prolongation in patients, and the potential for QT prolongation is not always equally correlated with TdP. Differences in risk between classes of psychotropic drugs, and between individual drugs within a class, may result from additional cellular effects of particular agents, which may influence the consequent effects of inhibition of repolarizing potassium current.

/pdf/psychotropic-drugs-cardiac-arrhythmia-and-sudden-death-2gdyqwqbyy.pdf

Psychotropic drugs, cardiac arrhythmia, and sudden death.

Because illicit drugs are now widely consumed, every doctor needs to know their acute medical consequences and complications. Here, we review the problems associated with the different drugs from a systems-based viewpoint. Apart from the respiratory depressant effect of opioids, crack cocaine is the most common cause of respiratory complications, mainly linked with its mode of use, with airway burns, pneumothorax, pneumomediastinum, and lung syndromes being well-recognised sequelae. Because of its marked cardiovascular effects, cocaine is also a major cause of coronary syndromes and myocardial infarction. Amphetamines may produce similar effects less commonly. Hyperthermia may occur with cocaine toxicity or with 3,4-methylenedioxymethamphetamine (MDMA) due to exertion or from serotonin syndrome. Cerebral haemorrhage may result from the use of amphetamines or cocaine. Hallucinations may follow consumption of LSD, amphetamines, or cocaine. MDMA is a major cause of acute severe hyponatraemia and also has been linked with hepatic syndromes. Collapse, convulsions, or coma may be caused in different circumstances by opioids, MDMA, or gamma hydroxybutyrate and may be aggravated by other sedatives, especially alcohol and benzodiazepines. Recognition of these acute complications is urgent, and treatment must be based on an understanding of the likely underlying problem as well as on basic principles of supportive care.

Review Clinical review: Major consequences of illicit drug consumption

/pdf/clinical-review-major-consequences-of-illicit-drug-1w1ggi8it7.pdf

Clinical review: Major consequences of illicit drug consumption

Cannabis as a precipitant of cardiovascular emergencies.

Antidepressant drugs are currently the mainstay of treatment for all but the mildest forms of depression. Their effectiveness in the management of depressive illness is undisputed and their effectiveness in preventing suicide, while not proven, may be assumed. Nevertheless, of all the drugs that are taken in lethal overdose, prescribed antidepressants are among the most common. Epidemiological studies from several countries have provided evidence of marked differences in overdose toxicity between drug classes and, in some cases, between individual drugs within a class, with some of the older tricyclic antidepressants (TCAs) being the most toxic. Over 80% of all deaths arising from overdose of antidepressant medication in the UK between 1987 and 1992 were caused by 2 drugs: amitriptyline and dothiepin. Taken alone, this figure conveys little information about the toxicity of either drug. However, when considered within an epidemiological context, the evidence suggests that both drugs are highly toxic in overdose, a conclusion that is supported by animal studies of the toxicity of TCAs and by clinical evidence of overdose toxicity. This paper reviews the epidemiological evidence concerning the acute toxicity of antidepressant drugs and considers the interplay of factors that contribute to the toxicity which occurs when they are taken in acute overdose. The inherent toxicity of the drug appears to be the crucial factor and, although less well researched, prescribing practices and perception of toxicity are probable contributory factors.

Epidemiology and Relative Toxicity of Antidepressant Drugs in Overdose

Depression is a common, recurrent, disabling and potentially fatal disorder. Its effect on quality of life is more severe than that of some other chronic medical conditions. Its cost burden (direct and indirect) has been estimated at $US26 billion to $US43.7 billion in the US (in 1990), and 3.4 billion pounds sterling in the UK (in 1992). With contemporary levels of diagnosis and treatment, and of treatment failure, the indirect economic losses to society from depression-associated morbidity and mortality may be up to 7 times the direct costs, with 69 to 98% of these costs related to morbidity. Impaired capacity while at work may equal absenteeism in terms of costs. Depression carries an increased risk of suicide and suicide attempts, both of which are costly. It is ironic, then, that the drugs used to treat depression account for 9% of poisoning deaths in England and Wales. The newer antidepressants are less toxic than the tricyclic antidepressants (TCAs). The physician's choice of antidepressant should be motivated primarily by clinical considerations, but cost implications are of increasing importance. In some healthcare systems, the expenditure associated with prescribing by doctors has been successfully modified, at least temporarily, by drug formularies, audit and feedback. This may be to the disadvantage of the selective serotonin (5-hydroxytryptamine: 5-HT) reuptake inhibitors; they have higher acquisition costs than the TCAs, since they are newer and lack cheaper generic forms, and definitive evidence of benefits may be inadequate or equivocal. However, market price is only one of many factors that should affect the prescriber, and the increasing trend towards cost containment policies is liable to lead to false economies.

John A. Henry

Papers

Review Clinical review: Major consequences of illicit drug consumption

Clinical review: Major consequences of illicit drug consumption

Cannabis as a precipitant of cardiovascular emergencies.

Epidemiology and Relative Toxicity of Antidepressant Drugs in Overdose

Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.